Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug EDK060 enters first human tests for nerve disease CMT1A

NCT ID NCT07140614

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This early-stage study tests a single dose of EDK060 in 28 adults with Charcot-Marie-Tooth type 1A, a genetic nerve disorder. The main goal is to see if the drug is safe and how it moves through the body, compared to a placebo. Participants are randomly assigned and neither they nor their doctors know who gets the real drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHARCOT-MARIE-TOOTH DISEASE TYPE 1A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • CIUSS de l´Estrie-CHUS- Hôpital Fleurimont

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Montreal Neurological Institute

    RECRUITING

    Montreal, Quebec, H3A 2B4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Ottawa Hospital

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHARCOT-MARIE-TOOTH DISEASE TYPE 1A